ArticleJournal of anaesthesiology, clinical pharmacology
Intravenous dexmedetomidine as an adjunct to subarachnoid block: A simple effective method of better perioperative efficacy.
Article in Journal of anaesthesiology, clinical pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 12 citations in OpenAlex.
- Comparison of the effect of dexmedetomidine intrathecal injection and intravenous infusion on subarachnoid blockade during knee arthroscopy procedures: a randomized controlled trial.BMC anesthesiology · 2024Trial
- Article
- Dexmedetomidine is superior to midazolam for sedation and cerebral protection in postoperative hypertensive intracerebral hemorrhage patients: a retrospective study.The Journal of international medical research · 2020Article
- The Effect of Different Doses of Intravenous Dexmedetomidine on the Properties of Subarachnoid Blockade: A Systematic Review and Meta-Analysis.Local and regional anesthesia · 2020Article
- Effects of intravenous dexmedetomidine on spinal anesthesia and sedation - A comparison of two different maintenance infusions.Journal of anaesthesiology, clinical pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimDexmedetomidine (D) is a α2 agonist, has anesthetic and analgesic-sparing property. The objective of this study was to evaluate the effect of intravenous (I.V.) dexmedetomidine on the duration of sensory and motor block, postoperative analgesia, the level of sedation and side effect. MATERIAL AND
methodsSixty patients were randomly divided into two groups of thirty each. Group D received dexmedetomidine infusion @1 mcg/kg over 10 min and then @ 0.6 mcg/kg/h for rest of duration during surgery, Group C (control) received a similar volume of normal saline infusion before spinal anesthesia with 3 ml of bupivacaine 0.5%. Time of onset and regression time for sensory and motor blockade, the maximum upper level of sensory blockade, duration of postoperative analgesia, Ramsay sedation score and hemodynamic parameters were recorded. Intraoperative bradycardia and atropine requirement along with other side effect were also recorded.
resultsThe duration of sensorimotor block was significantly longer in D Group (341.7 ± 20.8 min for sensory block and 278.0 ± 11.0 min for motor block) as compared to control group (329.5 ± 22.1 min for sensory block and 250.0 ± 14.8 min for motor block), which was statistically significant (
conclusionI.V. dexmedetomidine significantly prolongs the duration of sensory and motor block of bupivacaine spinal anesthesia. Dexmedetomidine provides an excellent sedation during surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.